COMMUNIQUÉS West-GlobeNewswire
-
Ally Medical ER Unleashes the Final Stretch of Its Pet Supply Drive with Over 7,000 Donations and a Dog Named Ally Bear
27/08/2026 -
Correction: Entera to Participate in Upcoming Fall Investor Conferences
27/08/2026 -
PRM Cosmetic Surgery Announces New Surgeon Training Initiative Led by Dr. Robert Rey
27/08/2026 -
Fangzhou Reports Sustained Revenue and Profit Growth as AI-Powered Chronic Care Strategy Gains Momentum
27/08/2026 -
Recovery.com’s Tom Farley to Emcee National Recovery Month Kickoff
27/08/2026 -
Foundation for Sarcoidosis Research to Host Mid-Atlantic Regional Sarcoidosis Summit in Philadelphia
27/08/2026 -
Benefits and Risks of Artificial Intelligence (AI) Scrutinized in the Journal of American Physicians and Surgeons
27/08/2026 -
Eascra Biotech Appoints Chief Scientific Officer to Lead Commercialization Push
27/08/2026 -
Entera to Participate in Upcoming Fall Investor Conferences
27/08/2026 -
Pluri Announces Pricing of $3.3 Million Registered Direct Offering and Concurrent Private Placement with a Single Healthcare Focused Institutional Investor
27/08/2026 -
Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027
27/08/2026 -
Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients’ Daily Lives and Quality of Life Between Episodes
27/08/2026 -
HealthEquity Reports Second Quarter Ended July 31, 2026 Financial Results
27/08/2026 -
Cardurion Pharmaceuticals Announces Late-Breaking Presentation of Phase 2 Results for Tovinontrine (CRD-750), a PDE9 Inhibitor, in Heart Failure
27/08/2026 -
Noah Medical Announces Collaboration to Advance Imaging in Robotic-Assisted Bronchoscopy
27/08/2026 -
MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism
27/08/2026 -
CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)
27/08/2026 -
Artelo Biosciences Announces Reverse Stock Split
27/08/2026 -
SL Science Highlights New FDA Drug Master File for GDT Cell-Derived Exosomes, Expanding the Regulatory Foundation of its Platform
27/08/2026
Pages